Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to investigate the role of
G-protein signaling modulator 2
in the carcinogenesis and progression of hepatocellular carcinoma. We previously showed that
G-protein signaling modulator 2
was upregulated in
hepatitis B
virus-related hepatocellular carcinoma tissues through a hierarchical clustering analysis. With this study, we first assessed the expression pattern of
G-protein signaling modulator 2
in hepatocellular carcinoma specimens and adjacent noncancerous tissues; clinical data were analyzed, along survival times, utilizing the Kaplan-Meier method. Moreover, the functions of
G-protein signaling modulator 2
were examined using small-interfering RNAs in vitro. The results showed that
G-protein signaling modulator 2
was clearly overexpressed in hepatocellular carcinoma tissues and cell lines and that the
G-protein signaling modulator 2
expression level was related to tumor size and
hepatitis B
virus infection. Furthermore,
G-protein signaling modulator 2
knockdown studies suggested that
G-protein signaling modulator 2
accelerates cell growth, cell cycle, migration, and invasion and inhibits apoptosis, acting as an oncogene in hepatocellular carcinoma. Western blotting indicated that silencing of
G-protein signaling modulator 2
in HepG2 and SMMC-7721 cells increased the expression levels of Bax, caspase-3, and E-cadherin, while notably suppressing the cyclin-dependent kinase 4, cyclin-dependent kinase 6, CyclinD1, Snail1, Vimentin, and matrix metallopeptidase 9 expression levels, compared with that in the control groups. In addition, we found that
G-protein signaling modulator 2
can affect the expression of key proteins involved in protein kinase B activation. In conclusion, high expression of
G-protein signaling modulator 2
was involved in the pathological processes of hepatocellular carcinoma through activation of the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, which may provide an attractive potential diagnostic biomarker and therapeutic target for treatment of hepatocellular carcinoma.
...
PMID:High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. 2834 29